Search results
Results from the WOW.Com Content Network
In blood vessels, it inhibits norepinephrine release and acts as a vasodilator; in the kidneys, it increases sodium excretion and urine output; in the pancreas, it reduces insulin production; in the digestive system, it reduces gastrointestinal motility and protects intestinal mucosa; and in the immune system, it reduces the activity of ...
Neurosecretion is the release of extracellular vesicles and particles from neurons, astrocytes, microglial and other cells of the central nervous system.These neurohormones, produced by neurosecretory cells, are normally secreted from nerve cells in the brain that then circulate into the blood.
Drug delivery to the brain is the process of passing therapeutically active molecules across the blood–brain barrier into the brain.This is a complex process that must take into account the complex anatomy of the brain as well as the restrictions imposed by the special junctions of the blood–brain barrier.
This response causes an increase in heart-rate, blood pressure, and accelerated breathing. The kidneys release glucose, providing energy to combat or flee the stressor. [12] Blood is redirected to the brain and major muscle groups, diverted away from energy consuming bodily functions unrelated to survival at the present time. [11]
Serotonin (/ ˌ s ɛr ə ˈ t oʊ n ɪ n, ˌ s ɪər ə-/) [6] [7] [8] or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter.Its biological function is complex, touching on diverse functions including mood, cognition, reward, learning, memory, and numerous physiological processes such as vomiting and vasoconstriction.
By means of cerebral autoregulation, the body is able to deliver sufficient blood containing oxygen and nutrients to the brain tissue for this metabolic need, and remove CO 2 and other waste products. Cerebral autoregulation refers to the physiological mechanisms that maintain blood flow at an appropriate level during changes in blood pressure ...
L-DOPA, a precursor of dopamine that crosses the blood–brain barrier, is used in the treatment of Parkinson's disease. For depressed patients where low activity of the neurotransmitter norepinephrine is implicated, there is only little evidence for benefit of neurotransmitter precursor administration.
Amphetamine, the prototypical monoamine releasing agent, which induces the release of dopamine and norepinephrine. [1]A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of one or more monoamine neurotransmitters from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitters and ...